What if: we can develop therapeutics to treat Alzheimer's disease and other Central Nervous System diseases...
Can you Imagine...
the Development of Central
Nervous System Therapeutics?
Alion is developing a pipeline of small molecule therapeutics targeting certain Central Nervous System diseases. Our therapeutics approach involves modulation of either protein-protein interactions or ion channels. In both instances, we have considerable experience and we have developed a proprietary computational means for the discovery of small molecules to modulate specific ion channel types.
Alion's technology dramatically reduces the time and cost of early stage drug development.
One Therapeutic Target | One Modulator | One Therapeutics
Using our proprietary computational designed to reduce the time and cost of early stage drug development, we are building a pipeline of small molecule therapeutics targeting Central Nervous System (CNS) diseases.
Here we focus on protein-protein interactions. Several candidate molecules have been indentified.
Alion has identified a number of small molecules that modulate our therapeutic targets for new Alzheimer’s disease and other CNS therapeutics.
A measure of success of any novel approach in the development of new therapeutics is the speed and cost effectiveness of the methods. By these measures Alion’s proprietary computational approach has passed the test.
According to the NIH in a 2015 program announcement, "There is no greater healthcare need than slowing or preventing Alzheimer’s disease." Today, therapeutic approaches to the development of an Alzheimer’s disease therapeutic have focused on the “magic bullet” approach. In this approach a single molecule is developed to target a protein, often amyloid-beta, in an attempt inhibit the formation of plaques. Alion’s approach has been quite different from the inception of the project. Our efforts are directed towards modulation of pathways of protein-protein interactions in a concerted effort to exert many simultaneous therapeutic effects.
Candidate small molecules have been identified for the treatment of Alzheimer’s Disease. Additionally, models have been developed and molecules suitable for testing as therapeutic leads to treat Parkinson’s Disease and Neuropathic Pain, have been identified.
Want to keep up to date with all our latest news and information? Enter your email below to be added to our mailing list.
All rights reserved by Alion Pharmaceuticals, 2019